Related Experiment Video
Updated: Feb 5, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis
Stephen M Smith1, O Hans Iwenofu2
1Department of Pathology & Laboratory Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Abstract:
Sarcomas are heterogenous malignant mesenchymal neoplasms. These are often notoriously difficult to treat particularly in the metastatic setting. There is therefore an urgent need for development of better and more efficacious targeted therapies. Cancer testis antigens (CTAs) are a family of proteins in which aberrant gene-activation and subsequent high level mRNA expression, are restricted to testicular germ cells and are seen in certain malignancies. Importantly, the restriction of this class of antigens to testicular germ cells and malignancies and not somatic tissue, makes them an excellent choice for targeted immunotherapy. The NY-ESO-1is the most immunogenic of CTA and has, of late, become well-studied for its diagnosis and potential treatment implications in sarcomas. This paper reviews both the role of NY-ESO-1 in the diagnosis of sarcomas, as well as the implications of this CTA in vaccine development and treatment of sarcomas.
Insights
NY-ESO-1, a cancer-testis antigen, shows promise for diagnosing and treating sarcomas. Its restricted expression makes it a target for effective immunotherapy and vaccine development in sarcoma treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Sarcomas are challenging malignant mesenchymal neoplasms, especially in metastatic stages.
- Targeted therapies are crucial for improving sarcoma treatment efficacy.
- Cancer-testis antigens (CTAs) are expressed in germ cells and some cancers, making them ideal for targeted immunotherapy.
Purpose of the Study:
- To review the diagnostic role of NY-ESO-1 in sarcomas.
- To explore the implications of NY-ESO-1 in sarcoma vaccine development and treatment.
Main Methods:
- Literature review focusing on NY-ESO-1 expression and function in sarcomas.
- Analysis of diagnostic and therapeutic potential of NY-ESO-1 in sarcoma research.
Main Results:
- NY-ESO-1 is a highly immunogenic CTA with diagnostic and therapeutic relevance in sarcomas.
- Its restricted expression pattern offers a unique target for immunotherapy.
Conclusions:
- NY-ESO-1 holds significant potential for advancing sarcoma diagnosis and treatment.
- Targeting NY-ESO-1 through vaccines and immunotherapies is a promising strategy for sarcomas.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:27Tumor Immunotherapy
01:22Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...
01:26Formulating and Validating Nursing Diagnosis I
There are thirteen domains...
01:10Documentation of Nursing Diagnosis
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
01:22Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...